Cytoreductive nephrectomy (CN) has been associated with perioperative morbidity, however, data are lacking regarding the risk of prolonged length of stay (pLOS) and delay to receipt of systemic therapy (ST). Mayo Clinic researchers conducted a study published in European Urology to evaluate the association of clinicopathologic features with postoperative complications, pLOS, and time to receipt of ST.
Recent Stories for Research
Papillary fibroelastomas (PFE) are benign neoplasms with little available outcome data. Mayo Clinic researchers conducted a study published in the Journal of the American College of Cardiology to describe the frequency and clinical course of patients with surgically removed PFE and echocardiographically suspected, but unoperated, PFE.
Newborn screening (NBS) has developed throughout the years into a public health prevention program aimed at identifying an increasing number of conditions for which early intervention can prevent premature mortality, morbidity, and disabilities. In a recent article published in the journal Seminars in Perinatology, Mayo Clinic researchers reviewed the current state of NBS for lysosomal storage disorders and discussed their importance in NBS programs.
Other Posts for Research
- Assessing the Genomic Landscape for Primary Central Nervous System Lymphomas
- Evaluation of cis-Regulatory Variation in Human Prostate Transcriptome
- Assessing Genetic Determinants in Momelotinib-Treated Patients with Myelofibrosis
- Glomerular C4d for Diagnosis of Proliferative Glomerulonephritis
- Examining Neuronal Pathology in Multiple System Atrophy
- Mayo Clinic Researchers Test FilmArray Blood Culture ID for Prosthetic Joint Infections
- Mayo Clinic Study Evaluating New Molecular Tests to Diagnose Infectious Diarrhea Receives High Honors at 2015 American Society for Microbiology General Meeting
- Implementing a Safer Blood Transfusion Process for Elective Surgery
- Clinicopathologic Characteristics for Leukocyte Cell-Derived Chemotaxin 2-Associated Amyloidosis
- The Effect of mTORC1 Inhibitor Everolimus in Patients with Relapsed T-Cell Lymphoma